Ab­b­Vie adds more stel­lar da­ta on ABT-494 — this time for atopic der­mati­tis

ABT-494 has de­liv­ered stel­lar re­sults in a Phase IIb study for atopic der­mati­tis, scor­ing a big win for Ab­b­Vie $AB­BV on a drug it counts as one of its most ex­cit­ing late-stage block­buster prospects.

The drug, AKA upadac­i­tinib, hand­i­ly whipped a place­bo group among treat­ment re­sis­tant pa­tients, with a 74% im­prove­ment in a key mea­sure of dis­ease sever­i­ty for the group tak­ing the high dose of their JAK1 drug. Up to 69% of the pa­tients tak­ing one of three dos­es achieved a 75% im­prove­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER